Bristol-Myers Squibb Company (BMY) Comparison with companies in other sectors?

Bristol-Myers Squibb Company has a share price of 2.04B. You can analyze Bristol-Myers Squibb Company (BMY) competitors across different market sectors through stock heatmaps.

What are BMY's NET and operating margins?

Bristol-Myers Squibb Company (BMY) operating margin is around 0.18, and net profit margin is approximately 0.11 as of the latest reports.

In what way does BMY's earnings per share (EPS) trend reflect its financial momentum?

Bristol-Myers Squibb Company (BMY) EPS is 2.68 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Bristol-Myers Squibb Company is 18.08, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Bristol-Myers Squibb Company?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Bristol-Myers Squibb Company like P/E which is 18.10, P/B which is 5.64, and PEG which is 0.11. Compare them with sector averages to evaluate if the stock is priced fairly.

Bristol-Myers Squibb Company

BMY•NYSE

Healthcare

Drug Manufacturers - General

$48.43

$-0.51(-1.04%)

Fundamental Analysis of Bristol-Myers Squibb Company (BMY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.68

P/E Ratio

18.08

ROE

0.32%

Net Margin

0.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$98.60B

Shares OutstandingTotal number of shares issued

$2.04B

Book Value/ShareNet worth per share

$8.59

Revenue/ShareAnnual revenue per share

$23.45

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.68

Net MarginNet income as percentage of revenue

11.38%

Operating MarginOperating income as percentage of revenue

18.45%

ROEReturn on shareholders' equity

31.93%

ROAReturn on total assets

5.86%

ROCEReturn on capital employed

12.85%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$6.44

Cash/ShareCash and equivalents per share

$5.80

FCF YieldFree cash flow as percentage of market cap

13.29%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$2.46

Dividend YieldAnnual dividend as percentage of stock price

5.08%

Financial Ratios Analysis data is not available for BMYFinancial Ratios Analysis details for BMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BMYSector Benchmarking details for BMY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Bristol-Myers Squibb Company Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Bristol-Myers Squibb Company. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Bristol-Myers Squibb Company's unique business strengths and challenges.

Key Financial Metrics for Bristol-Myers Squibb Company

For Bristol-Myers Squibb Company, essential financial indicators include EPS 2.68, PE 18.08, and ROE 0.32. These key ratios reveal insights into Bristol-Myers Squibb Company's profitability, valuation, and operational health. Understanding these metrics enables you to compare Bristol-Myers Squibb Company with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Bristol-Myers Squibb Company

Metrics like Net Margin 11.38% and ROA 5.86% shed light on how well Bristol-Myers Squibb Company is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Bristol-Myers Squibb Company can sustain its operations and continue growing in the future.

Valuation and Market Position of Bristol-Myers Squibb Company

Using ratios such as P/B Ratio 5.64 and PEG Ratio 0.11, investors can assess whether Bristol-Myers Squibb Company is appropriately valued based on its financials and growth potential. These figures, combined with Bristol-Myers Squibb Company's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Bristol-Myers Squibb Company

Financial health indicators, such as Debt/Equity Ratio 2.95 and Cash Flow $6.44, provide a snapshot of Bristol-Myers Squibb Company's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Bristol-Myers Squibb Company, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Bristol-Myers Squibb Company

Investing in Bristol-Myers Squibb Company based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Bristol-Myers Squibb Company focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;